About Mind Medicine (MindMed) Inc.
https://www.mindmed.coMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.
CEO
Robert Barrow
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-08-29 | Reverse | 1:15 |
| 2020-03-03 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.94M
Value:$89.15M
BLACKROCK INC.
Shares:5.38M
Value:$80.87M
COMMODORE CAPITAL LP
Shares:3.23M
Value:$48.44M
Summary
Showing Top 3 of 221
About Mind Medicine (MindMed) Inc.
https://www.mindmed.coMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $45.67M ▲ | $-67.27M ▼ | 0% | $-0.78 ▼ | $-65.98M ▼ |
| Q2-2025 | $0 | $40.9M ▲ | $-42.74M ▼ | 0% | $-0.5 ▼ | $-40.41M ▼ |
| Q1-2025 | $0 | $32.16M ▼ | $-23.35M ▲ | 0% | $-0.27 ▲ | $-22.75M ▲ |
| Q4-2024 | $0 | $32.46M ▲ | $-34.74M ▼ | 0% | $-0.41 ▼ | $-34.09M ▼ |
| Q3-2024 | $0 | $24.79M | $-13.68M | 0% | $-0.18 | $-1.12M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $209.07M ▲ | $236.92M ▼ | $106.32M ▲ | $130.6M ▼ |
| Q2-2025 | $182.99M ▼ | $265.09M ▼ | $79.69M ▲ | $185.4M ▼ |
| Q1-2025 | $212.44M ▼ | $275.32M ▼ | $52.52M ▼ | $222.81M ▼ |
| Q4-2024 | $273.74M ▼ | $302.15M ▼ | $60.7M ▲ | $241.45M ▼ |
| Q3-2024 | $295.28M | $319.77M | $57.58M | $262.19M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-67.27M ▼ | $-29.57M ▲ | $15.41M ▲ | $749K ▼ | $-13.43M ▲ | $-29.57M ▲ |
| Q2-2025 | $-42.74M ▼ | $-29.6M ▼ | $-39.54M ▲ | $19.65M ▲ | $-49.46M ▲ | $-29.6M ▼ |
| Q1-2025 | $-23.35M ▲ | $-29.42M ▼ | $-162.46M ▼ | $1M ▼ | $-190.89M ▼ | $-29.42M ▼ |
| Q4-2024 | $-34.74M ▼ | $-25.35M ▼ | $0 | $3.81M ▼ | $-21.54M ▼ | $-25.35M ▼ |
| Q3-2024 | $-13.68M | $-17.19M | $0 | $69.35M | $52.15M | $-17.19M |
CEO
Robert Barrow
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-08-29 | Reverse | 1:15 |
| 2020-03-03 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 54
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.94M
Value:$89.15M
BLACKROCK INC.
Shares:5.38M
Value:$80.87M
COMMODORE CAPITAL LP
Shares:3.23M
Value:$48.44M
Summary
Showing Top 3 of 221